Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.
Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALMS alumis.com
Alumis Inc. is a late-stage biopharmaceutical company developing oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated, neuroinflammatory and neurodegenerative diseases, using a proprietary data analytics platform and precision approach.
Its lead candidate, envudeucitinib, is a highly selective oral TYK2 inhibitor that completed the Phase 3 ONWARD program in moderate-to-severe plaque psoriasis. An NDA submission is planned for 4Q 2026. Envudeucitinib was also studied in systemic lupus erythematosus in the Phase 2b LUMUS trial, which missed its endpoints overall but showed responses in IFNGS-high patients.
A second candidate, A-005, is a CNS-penetrant TYK2 inhibitor targeting conditions such as Parkinson's disease, with a Phase 2 biomarker trial planned for 2027. The pipeline also includes several preclinical programs.
Alumis currently earns collaboration revenue under a collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. It previously completed a merger with ACELYRIN, Inc. Updated
Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.
Alumis Inc. is a late-stage biopharmaceutical company developing oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated, neuroinflammatory and neurodegenerative diseases, using a proprietary data analytics platform and precision approach.
The Wall Street consensus 12-month price target for ALMS is $25.38.